Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Jennifer Rebholz
Male bone cancer (MaBC) is a clinically uncommon condition that accounts for about 1 of all cases of bone cancer. Yet, over the past few decades, MaBC has become more common. Age, black race, inherited mutations, liver cirrhosis, malformed testicles, family history of bone cancer, and age are risk factors for MaBC. The majority of mature MaBC cases come with painless lumps, and at the time of consultation, at least one lymph node is implicated in nearly half of the cases. MaBC is treated similarly to womanish bone cancer (FeBC), but this is largely because prospective research on MaBC cases are lacking. Surgery, adjuvant radiation, endocrine therapy, and chemotherapy are some of the treatment options. To perform clinical studies for MaBC or include MaBC cases in FeBC trials, ongoing transnational conflict is required. This will aid doctors in providing better care for MaBC clients.